VEGFA and glioblastoma: Different strategies have been used to inhibit VEGF signaling in glioblastoma, anti-VEGF antibody therapy, and tyrosine kinase receptor inhibitors, alone or in combination with other conventional therapeutic strategies, and have had dissimilar results, including prolonging survival in some patients or no benefits in terms of overall survival, and a resistance to anti-VEGF therapy has also been observed in some patients [144].